JP7419073B2 - Ｔ細胞および／またはｈｌａ受容体の標的化破壊 - Google Patents
Ｔ細胞および／またはｈｌａ受容体の標的化破壊 Download PDFInfo
- Publication number
- JP7419073B2 JP7419073B2 JP2019568660A JP2019568660A JP7419073B2 JP 7419073 B2 JP7419073 B2 JP 7419073B2 JP 2019568660 A JP2019568660 A JP 2019568660A JP 2019568660 A JP2019568660 A JP 2019568660A JP 7419073 B2 JP7419073 B2 JP 7419073B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- gene
- zfn
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title description 72
- 230000006378 damage Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 441
- 108090000623 proteins and genes Proteins 0.000 claims description 292
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 282
- 238000003776 cleavage reaction Methods 0.000 claims description 153
- 230000007017 scission Effects 0.000 claims description 153
- 108091008874 T cell receptors Proteins 0.000 claims description 132
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 121
- 230000004048 modification Effects 0.000 claims description 114
- 238000012986 modification Methods 0.000 claims description 114
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 112
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 97
- 230000014509 gene expression Effects 0.000 claims description 87
- 102000040430 polynucleotide Human genes 0.000 claims description 67
- 108091033319 polynucleotide Proteins 0.000 claims description 67
- 239000002157 polynucleotide Substances 0.000 claims description 67
- 108700019146 Transgenes Proteins 0.000 claims description 59
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 48
- 239000011701 zinc Substances 0.000 claims description 48
- 229910052725 zinc Inorganic materials 0.000 claims description 48
- 238000003780 insertion Methods 0.000 claims description 46
- 230000037431 insertion Effects 0.000 claims description 46
- 210000000130 stem cell Anatomy 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 42
- 101150076800 B2M gene Proteins 0.000 claims description 41
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 38
- 101710185494 Zinc finger protein Proteins 0.000 claims description 29
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims description 29
- 238000012217 deletion Methods 0.000 claims description 29
- 230000037430 deletion Effects 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000010362 genome editing Methods 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 8
- 210000003289 regulatory T cell Anatomy 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 101150095542 tap gene Proteins 0.000 claims description 5
- 101150118346 HLA-A gene Proteins 0.000 claims description 4
- 101150000578 HLA-B gene Proteins 0.000 claims description 4
- 101150035071 HLA-C gene Proteins 0.000 claims description 4
- 101150043532 CISH gene Proteins 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 description 156
- 230000004568 DNA-binding Effects 0.000 description 128
- 102000004169 proteins and genes Human genes 0.000 description 122
- 235000018102 proteins Nutrition 0.000 description 118
- 239000013598 vector Substances 0.000 description 84
- 150000007523 nucleic acids Chemical class 0.000 description 80
- 108020004414 DNA Proteins 0.000 description 76
- 102000039446 nucleic acids Human genes 0.000 description 76
- 108020004707 nucleic acids Proteins 0.000 description 76
- 230000027455 binding Effects 0.000 description 71
- 125000003729 nucleotide group Chemical group 0.000 description 52
- 239000002773 nucleotide Substances 0.000 description 51
- 230000035772 mutation Effects 0.000 description 48
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 102000004196 processed proteins & peptides Human genes 0.000 description 43
- 230000004927 fusion Effects 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 41
- 108020004999 messenger RNA Proteins 0.000 description 37
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 32
- 230000000694 effects Effects 0.000 description 32
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 31
- 102000040945 Transcription factor Human genes 0.000 description 31
- 108091023040 Transcription factor Proteins 0.000 description 31
- 108020001507 fusion proteins Proteins 0.000 description 31
- 102000037865 fusion proteins Human genes 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 238000012239 gene modification Methods 0.000 description 26
- 239000000427 antigen Substances 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 239000012634 fragment Substances 0.000 description 24
- 230000010354 integration Effects 0.000 description 24
- 230000004913 activation Effects 0.000 description 23
- 238000010453 CRISPR/Cas method Methods 0.000 description 22
- 108010077544 Chromatin Proteins 0.000 description 22
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 210000003483 chromatin Anatomy 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 20
- 238000013461 design Methods 0.000 description 19
- 238000001415 gene therapy Methods 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 18
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 18
- 230000005782 double-strand break Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 238000012546 transfer Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 108020005004 Guide RNA Proteins 0.000 description 16
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 16
- 230000001413 cellular effect Effects 0.000 description 16
- 230000005017 genetic modification Effects 0.000 description 16
- 235000013617 genetically modified food Nutrition 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 14
- 102000004533 Endonucleases Human genes 0.000 description 14
- 108010042407 Endonucleases Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000004520 electroporation Methods 0.000 description 14
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 14
- 108091033409 CRISPR Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 239000013603 viral vector Substances 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 12
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 11
- 230000002103 transcriptional effect Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000006471 dimerization reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 230000002779 inactivation Effects 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 230000001177 retroviral effect Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 230000007018 DNA scission Effects 0.000 description 7
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 7
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 description 7
- 108091028113 Trans-activating crRNA Proteins 0.000 description 7
- 238000011467 adoptive cell therapy Methods 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- -1 gpA33 Proteins 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241000589634 Xanthomonas Species 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 5
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 5
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 4
- 101710096438 DNA-binding protein Proteins 0.000 description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 4
- 241000589499 Thermus thermophilus Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 238000012226 gene silencing method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 210000004287 null lymphocyte Anatomy 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000037426 transcriptional repression Effects 0.000 description 4
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 108010013043 Acetylesterase Proteins 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000008682 Argonaute Proteins Human genes 0.000 description 3
- 108010088141 Argonaute Proteins Proteins 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 3
- 108091036060 Linker DNA Proteins 0.000 description 3
- 108700005089 MHC Class I Genes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 102100026967 T cell receptor beta chain MC.7.G5 Human genes 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000005783 single-strand break Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 101001030716 Arabidopsis thaliana Histone deacetylase HDT1 Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 2
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 2
- 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 2
- 101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 108700040121 Protein Methyltransferases Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 241000589771 Ralstonia solanacearum Species 0.000 description 2
- 101100087805 Ralstonia solanacearum rip19 gene Proteins 0.000 description 2
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 241000256248 Spodoptera Species 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 230000009438 off-target cleavage Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000021127 protein binding proteins Human genes 0.000 description 2
- 108091011138 protein binding proteins Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000893512 Aquifex aeolicus Species 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 101150077194 CAP1 gene Proteins 0.000 description 1
- 101150014715 CAP2 gene Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150091887 Ctla4 gene Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102100031565 Cytidine and dCMP deaminase domain-containing protein 1 Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710155335 DELLA protein SLR1 Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100441545 Drosophila melanogaster Cfp1 gene Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 101100049549 Enterobacteria phage P4 sid gene Proteins 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010041384 HLA-DPA antigen Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 101150035620 HLA-DRA gene Proteins 0.000 description 1
- 101100028493 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) pan2 gene Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010049606 Hepatocyte Nuclear Factors Proteins 0.000 description 1
- 102000008088 Hepatocyte Nuclear Factors Human genes 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
- 101100437218 Homo sapiens B2M gene Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000615495 Homo sapiens Methyl-CpG-binding domain protein 3 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 101000702560 Homo sapiens Probable global transcription activator SNF2L1 Proteins 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 1
- 101100194594 Homo sapiens RFX5 gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000702544 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 Proteins 0.000 description 1
- 101000649068 Homo sapiens Tapasin Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 1
- 101150047851 IL2RG gene Proteins 0.000 description 1
- 102000044753 ISWI Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 1
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100046877 Oryza sativa subsp. japonica TRAB1 gene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101100440941 Petroselinum crispum CPRF1 gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 101150074379 RFX5 gene Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101150065817 ROM2 gene Proteins 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 101100272715 Ralstonia solanacearum (strain GMI1000) brg11 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101001025539 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Homothallic switching endonuclease Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- 229940046176 T-cell checkpoint inhibitor Drugs 0.000 description 1
- 239000012644 T-cell checkpoint inhibitor Substances 0.000 description 1
- 101150011263 Tap2 gene Proteins 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000007720 allelic exclusion Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000000005 bacterial plant pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 1
- 108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 201000008017 ovarian lymphoma Diseases 0.000 description 1
- 101150081585 panB gene Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022137773A JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521132P | 2017-06-16 | 2017-06-16 | |
| US62/521,132 | 2017-06-16 | ||
| US201762542052P | 2017-08-07 | 2017-08-07 | |
| US62/542,052 | 2017-08-07 | ||
| US201762573956P | 2017-10-18 | 2017-10-18 | |
| US62/573,956 | 2017-10-18 | ||
| PCT/US2018/037844 WO2018232296A1 (en) | 2017-06-16 | 2018-06-15 | Targeted disruption of t cell and/or hla receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137773A Division JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524994A JP2020524994A (ja) | 2020-08-27 |
| JP2020524994A5 JP2020524994A5 (enExample) | 2021-06-17 |
| JP7419073B2 true JP7419073B2 (ja) | 2024-01-22 |
Family
ID=64656803
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Active JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2022137773A Active JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137773A Active JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230295563A1 (enExample) |
| EP (1) | EP3638783A4 (enExample) |
| JP (3) | JP7419073B2 (enExample) |
| KR (1) | KR102708624B1 (enExample) |
| CN (1) | CN110997913B (enExample) |
| AU (1) | AU2018283310B2 (enExample) |
| BR (1) | BR112019026622A2 (enExample) |
| CA (1) | CA3066641A1 (enExample) |
| IL (1) | IL271298A (enExample) |
| SG (1) | SG11201911729SA (enExample) |
| WO (1) | WO2018232296A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3573464A4 (en) * | 2017-01-26 | 2020-12-30 | Sangamo Therapeutics, Inc. | B CELL ENGINEERING |
| WO2020061161A1 (en) * | 2018-09-18 | 2020-03-26 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
| CN116323921A (zh) | 2020-10-28 | 2023-06-23 | 桑格摩生物治疗股份有限公司 | 从人多能干细胞生成cd4+效应t细胞和调节性t细胞 |
| CN113846070B (zh) * | 2021-10-18 | 2023-05-16 | 翌圣生物科技(上海)股份有限公司 | 高活性的mTET2酶突变体、其编码DNA及其应用 |
| CN118813625B (zh) * | 2024-06-17 | 2025-08-26 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA及应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110126317A1 (en) | 2008-04-21 | 2011-05-26 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
| WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| JP2017508468A (ja) | 2014-03-11 | 2017-03-30 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| JP2017514476A (ja) | 2014-05-01 | 2017-06-08 | ユニバーシティ・オブ・ワシントン | アデノウイルスベクターを用いたインビボでの遺伝子操作 |
| JP2018537112A (ja) | 2015-12-18 | 2018-12-20 | サンガモ セラピューティクス， インコーポレイテッド | Ｍｈｃ細胞受容体の標的化破壊 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235395A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| EP2686417B1 (de) * | 2011-03-17 | 2016-06-08 | Miltenyi Biotec GmbH | Tcralpha/beta-depletierte zellpräparationen |
| WO2012127464A2 (en) * | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| WO2015031619A1 (en) * | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| ES2983043T3 (es) * | 2015-12-18 | 2024-10-21 | Sangamo Therapeutics Inc | Alteración dirigida del receptor de células T |
| MX2020001594A (es) * | 2017-08-08 | 2020-12-09 | Sangamo Therapeutics Inc | Direccionamiento celular mediado por receptor de antigeno quimerico. |
| JP7275152B2 (ja) * | 2018-02-08 | 2023-05-17 | サンガモ セラピューティクス， インコーポレイテッド | 操作された標的特異的なヌクレアーゼ |
-
2018
- 2018-06-15 WO PCT/US2018/037844 patent/WO2018232296A1/en not_active Ceased
- 2018-06-15 AU AU2018283310A patent/AU2018283310B2/en not_active Expired - Fee Related
- 2018-06-15 BR BR112019026622-4A patent/BR112019026622A2/pt not_active IP Right Cessation
- 2018-06-15 CA CA3066641A patent/CA3066641A1/en active Pending
- 2018-06-15 JP JP2019568660A patent/JP7419073B2/ja active Active
- 2018-06-15 CN CN201880052991.4A patent/CN110997913B/zh active Active
- 2018-06-15 EP EP18818351.1A patent/EP3638783A4/en active Pending
- 2018-06-15 KR KR1020207000964A patent/KR102708624B1/ko active Active
- 2018-06-15 SG SG11201911729SA patent/SG11201911729SA/en unknown
-
2019
- 2019-12-10 IL IL271298A patent/IL271298A/en unknown
-
2022
- 2022-08-31 JP JP2022137773A patent/JP7482176B2/ja active Active
- 2022-10-21 US US17/971,071 patent/US20230295563A1/en active Pending
-
2024
- 2024-02-07 JP JP2024017157A patent/JP2024036610A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110126317A1 (en) | 2008-04-21 | 2011-05-26 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
| JP2017508468A (ja) | 2014-03-11 | 2017-03-30 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| JP2017514476A (ja) | 2014-05-01 | 2017-06-08 | ユニバーシティ・オブ・ワシントン | アデノウイルスベクターを用いたインビボでの遺伝子操作 |
| WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| JP2018537112A (ja) | 2015-12-18 | 2018-12-20 | サンガモ セラピューティクス， インコーポレイテッド | Ｍｈｃ細胞受容体の標的化破壊 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3638783A1 (en) | 2020-04-22 |
| CA3066641A1 (en) | 2018-12-20 |
| SG11201911729SA (en) | 2020-01-30 |
| KR102708624B1 (ko) | 2024-09-20 |
| EP3638783A4 (en) | 2021-03-10 |
| IL271298A (en) | 2020-01-30 |
| CN110997913A (zh) | 2020-04-10 |
| AU2018283310A1 (en) | 2020-01-02 |
| KR20200018623A (ko) | 2020-02-19 |
| JP2022164822A (ja) | 2022-10-27 |
| CN110997913B (zh) | 2024-05-28 |
| WO2018232296A1 (en) | 2018-12-20 |
| JP2024036610A (ja) | 2024-03-15 |
| US20230295563A1 (en) | 2023-09-21 |
| JP2020524994A (ja) | 2020-08-27 |
| BR112019026622A2 (pt) | 2020-06-30 |
| JP7482176B2 (ja) | 2024-05-13 |
| AU2018283310B2 (en) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7462699B2 (ja) | Ｔ細胞受容体の標的化破壊 | |
| JP7541550B2 (ja) | Ｍｈｃ細胞受容体の標的化破壊 | |
| JP7482176B2 (ja) | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 | |
| US11512287B2 (en) | Targeted disruption of T cell and/or HLA receptors | |
| HK1260200B (zh) | Mhc细胞受体的靶向破坏 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210427 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230331 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231004 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240110 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7419073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |